Bank of New York Mellon Corp bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 31,250 shares of the company’s stock, valued at approximately $291,000. Bank of New York Mellon Corp owned 0.16% of Kura Oncology as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the company. State of Wisconsin Investment Board bought a new stake in shares of Kura Oncology in the 2nd quarter valued at about $102,000. Rhumbline Advisers acquired a new stake in Kura Oncology in the 2nd quarter worth approximately $131,000. Schwab Charles Investment Management Inc. acquired a new stake in Kura Oncology in the 2nd quarter worth approximately $226,000. Goldman Sachs Group Inc. acquired a new stake in Kura Oncology in the 1st quarter worth approximately $533,000. Finally, Oppenheimer & Co. Inc. boosted its stake in Kura Oncology by 14.7% in the 1st quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after purchasing an additional 1,600 shares in the last quarter. Institutional investors and hedge funds own 40.56% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Bank of New York Mellon Corp Takes Position in Kura Oncology, Inc. (KURA)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/11/04/bank-of-new-york-mellon-corp-takes-position-in-kura-oncology-inc-kura.html.
Kura Oncology, Inc. (KURA) opened at $14.95 on Friday. The company has a current ratio of 10.80, a quick ratio of 10.79 and a debt-to-equity ratio of 0.16.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.03. analysts forecast that Kura Oncology, Inc. will post -1.54 earnings per share for the current year.
A number of analysts recently commented on KURA shares. Cowen and Company started coverage on shares of Kura Oncology in a research note on Thursday, September 7th. They issued an “outperform” rating for the company. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research note on Saturday, September 9th. ValuEngine upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Finally, Citigroup Inc set a $13.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.00.
Kura Oncology Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
What are top analysts saying about Kura Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kura Oncology Inc. and related companies.